**Section 2081.40 Long Term Care Pharmacies Responsibility**

LTC pharmacies shall transmit the patient medication profiles to the PMP weekly (see 720 ILCS 570/316(c)). The Department shall impose a civil fine of $100 per day for willful failure to comply with statutory reporting requirements. Assessment of the fine begins on the day after the report was required to be submitted and ends on the day the failure to report is remedied. Fines shall be payable to the Prescription Monitoring Program.

a) This information shall include, but not be limited to, all the following data fields to provide the clinical oversight required by Section 5-5.12(f) of the Public Aid Code or as modified by DPH, HFS or DHS:

1) Dispenser DEA number.

2) Name of the medication as listed in Appendix A.

3) Dispenser name and address.

4) Patient information that should be kept up to date at all times:

A) Patient's name.

B) Patient ID.

C) Patient sex (M for male, F for female or U for unknown).

D) Patient birth date (yyyymmdd – year, month, day).

E) Patient ethnicity (if available).

F) Patient location code (LTC facility State provider number and corresponding location at the facility, i.e., unit and room).

G) Pre-existing conditions.

H) Patient weight, when available electronically.

I) Patient height, when available electronically.

5) For each prescription dispensed, the following information must be included:

A) The NDC identification number of the Schedule II, III, IV or V drugs or select drugs.

B) Quantity of the drug dispensed.

C) Dosing of the drug dispensed.

D) Date when the drug was dispensed.

E) Date prescription was written.

F) Prescriber DEA number.

G) Prescriber full name.

H) Diagnosis.

I) Days' supply (based on dispensed quantity).

6) For any patient admissions to acute care facilities, the following information shall be included:

A) Date admitted, if known to the dispenser.

B) Date discharged, if discharged at time of transmission, if known to the dispenser.

C) Reason for admission, if known to the dispenser.

D) Any changes to medication therapy involving medications in Appendix A, if known to the dispenser.

b) As directed by the Clinical Director for PMP, aggregate data and specialized reports may be developed relative to the selected drugs for clinical studies as covered under Art. VIII, Part. 21 of the Code of Civil Procedure [735 ILCS 5] (Medical Studies).

(Source: Amended at 47 Ill. Reg. 10948, effective July 7, 2023)